NRXP

NRx Pharmaceuticals, Inc.
NasdaqCMUSDEQUITY Healthcare DELAYED
Last price
3.56
▲ 0.05 (1.42%)
MARKET ·

Price

Open
3.52
Prev close
3.51
Day high
3.60
Day low
3.44
Volume
610.43K
Market cap
$154.13M
P/E (TTM)
52W range
1.62 – 5.06

Trailing performance

Price return · vs SPY
Returnvs SPY
1W
+8.87% +10.2%
1M
-13.38% -17.1%
3M
+16.34% +13.2%
6M
+93.48% +82.4%
YTD
+31.37% +19.1%
1Y
+35.88% +15.9%
3Y
+8.87% -65.3%
5Y

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported
Market cap$154.13M
Enterprise value$112.58M
Revenue (TTM)$2.29M
Gross profit$1.16M
EBITDA$-17.06M
Net income$-24.54M
EPS (TTM)$-0.51
Free cash flow$-8.54M
Total cash$6.71M
Total debt$934.00K
Book value / share$-0.50
Shares outstanding43.30M
Float31.23M
Short % of float15.97%
Dividend yield
Beta (5Y)2.18

Valuation & profitability ratios

Account required
Trailing P/E
Forward P/E7.12
PEG ratio
Price / sales
Price / book
EV / revenue49.10
EV / EBITDA-6.60
Gross margin50.46%
Operating margin-444.57%
Profit margin0.00%
Return on equity
Return on assets-110.22%
Debt / equity
Current ratio0.29
Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Financial statements

Annual · as reported
Last 4 fiscal years
Line item2025202420232022
Total revenue$1.23M$0$0$0
Cost of revenue$0$0$0$0
Gross profit$0$0$0$0
R&D
SG&A
Operating income
Pre-tax income
Tax provision$0$0$0$0
Net income-$28.62M-$25.13M$0$0
EBIT$0$0$0$0

Earnings

History & consensus estimates
Reported vs expected · EPS
QuarterEst.ActualSurprise
Jun 2026 -0.13-0.24 -87.8%
Mar 2026 -0.11-0.04 +59.6%
Dec 2025 -0.080.18 +329.1%
Sep 2025 -0.02-0.51 -2,938.4%
Forward consensus
PeriodEPSAnalystsRevenueGrowth
Current quarter -0.08 1 $2.66M +997.5%
Next quarter -0.03 1 $8.17M +731.2%
Current year -0.36 1 $13.88M +1,033.4%
Next year 0.50 1 $156.92M +1,030.1%

Analyst targets & ownership

Account required
Mean target$38.25
High target$49.00
Low target$10.00
Implied upside974.44%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders7.58%
Held by institutions32.42%
Institutions holding53
Free account required

Price targets, consensus spread, insider and institutional ownership.

Insider net activity

6m · Form 4 rollup
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
Net transactions
0
Buys less sells
Sell : buy shares
Not enough filings
Insider-held shares
2.74M
Total on file

Insider transactions

Account required
DateInsiderAction SharesValueHeld
Dec 17, 24
JAVITT JONATHAN C
Chairman of the Board
BUY 40.00K $65.60K Direct
What this is, and what it is not

These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.

A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.

This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.

Free account required

Officer and director trades in their own stock, straight from Form 4 filings.

Insider holders

1 reporting
NameRelationShares heldLatest
JAVITT JONATHAN C
Chairman of the Board 1.52M Purchase

Moving averages & technicals

Computed from 2Y daily closes
SMA 10
3.40
+4.74% from price
SMA 20
3.33
+6.79% from price
SMA 50
3.75
-5.08% from price
SMA 100
3.44
+3.46% from price
SMA 200
2.80
+27.18% from price
EMA 12
3.43
+3.93% from price
EMA 26
3.51
+1.32% from price
EMA 50
3.57
-0.20% from price
RSI (14)
51.2
Neutral
MACD (12,26,9)
-0.09
Hist 0.05
ATR (14)
0.33
9.36% of price
Realised vol 30D
78.9%
Annualised
Bollinger upper
3.69
20, 2σ
Bollinger lower
2.98
20, 2σ
50 / 200 cross
Golden
3.75 vs 2.80
Trend bias
Above 200
+27.18%

Risk profile

Daily returns · 1Y window
Beta vs SPY
2.03
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
78.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-54.2%
Peak to trough
Max drawdown 5Y
-99.3%
Peak to trough
ATR 14
0.33
9.36% of price
Beta (reported)
2.18
5Y monthly, from filing

Unusual options activity

Account required
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
Free account required

Contracts trading at or above their open interest, ranked by notional and where the print landed.

Options analytics

Account required
Put / call volume
0.11
Call-heavy session
Put / call open interest
0.08
Positioning, not flow
Max pain
2.50
-29.8% from spot
ATM implied vol
100.0%
Nearest strike to spot
Skew (10% OTM)
-3.1%
Calls bid over puts
Call volume
156
Contracts, this expiry
Put volume
17
Contracts, this expiry
Heaviest call OI
2.50
3.97K contracts
Heaviest put OI
2.50
426 contracts

Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.

Free account required

Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.

Options chain

Account required
ExpirySpot 3.56
Calls
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Puts
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.